This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Osaka Industrial Promotion Organization. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: Kenji Miyado: Innovator in Osteoporosis and Chronic Obstructive Pulmonary Disease Research
Introduction
Kenji Miyado is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of model animals for studying osteoporosis and chronic obstructive pulmonary disease (COPD). His innovative work aims to enhance the understanding and treatment of these conditions.
Latest Patents
Miyado holds a patent for a CD9/CD81 double-deficient non-human animal. The objective of this invention is to provide a model animal that effectively exhibits the pathological conditions associated with low-turnover osteoporosis and COPD. This model can be utilized for screening therapeutic agents aimed at treating osteoporosis and COPD. The invention details a non-human animal with deficiencies in genes coding for CD9 and CD81, specifically in somatic cells. It also outlines methods for using this animal as a model for osteoporosis and COPD, including steps to measure osteogenesis inhibition and phenotypic similarities to COPD.
Career Highlights
Kenji Miyado is affiliated with the Osaka Industrial Promotion Organization, where he continues to advance his research. His work has garnered attention for its potential impact on therapeutic developments in osteoporosis and COPD.
Collaborations
Miyado has collaborated with notable colleagues, including Eisuke Mekada and Isao Tachibana. These partnerships have contributed to the depth and breadth of his research endeavors.
Conclusion
Kenji Miyado's innovative contributions to the field of biomedical research, particularly through his patent on a non-human animal model, highlight his commitment to advancing the understanding of osteoporosis and chronic obstructive pulmonary disease. His work is poised to facilitate the development of effective therapeutic agents for these significant health challenges.